 | | Vol. 8.27 – 22 July, 2020 |
| |
|
|
| Researchers conducted a Phase I/II, single-blind, randomized controlled trial in five trial sites in the UK of a chimpanzee adenovirus-vectored vaccine expressing the SARS-CoV-2 spike protein compared with a meningococcal conjugate vaccine as control.
[Lancet] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Monocytes/macrophages were the most enriched immune cell types in the lungs of COVID-19 patients and appeared to have a central role in the pathogenicity of the disease.
[Cell Metabolism] |
|
|
|
| Investigators implemented a structure-based vector analysis of available β-CoV S-protein structures. Despite an overall similarity in domain organization, they found that S-proteins from different β-CoVs displayed distinct configurations.
[Nature Structural & Molecular Biology] |
|
|
|
| Upon entry into the host, the virus bound to the extracellular domain of angiotensin-I converting enzyme 2 (ACE2) in nasal, lung, and gut epithelial cells through its spike glycoprotein subunit S1.
[Diabetes] |
|
|
|
| Investigators provide the first experimental data to investigate the capacity of SARS-CoV-2 to infect and be transmitted by mosquitoes.
[Scientific Reports] |
| | MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Scientists showed that the late HIV-1 accessory protein Vpu hijacked DNA repair mechanisms to promote degradation of nuclear viral cDNA in cells that were already productively infected.
[Nature Microbiology] |
|
|
|
| Researchers used the Mexican tetra Astyanax mexicanus to understand how loss of parasite diversity influences the evolutionary trajectory of the vertebrate immune system, by comparing river with cave morphotypes.
[Nature Ecology & Evolution] |
|
|
|
| Plasmablast response after the first immunization was exclusively directed to the conserved hemagglutinin stem region and came from memory B cells.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists formally tested the role of effector function in vivo by comparing the rate and timing of plasma-virus clearance in response to a single-dose treatment with either unmodified neutralizing monoclonal antibodies or those with either reduced or augmented Fc function.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Intraperitoneal injections of CD4-CCR5-VLP produced only subneutralizing plasma concentrations in HIV-1–infected humanized mice but elicited CD4-binding site mutations that reduced viral fitness.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Investigators showed that the proportion of Mycobacterium tuberculosis-specific CD4 T cells expressing CD153 was significantly reduced in active tuberculosis patients compared to latently infected persons.
[Mucosal Immunology] |
|
|
|
| The authors determined the chronological distribution of hepatitis E virus (HEV) in various tissues of HEV-challenged miniature pigs and to investigate the mechanisms underlying HEV-induced cell death in the pancreas and liver.
[Scientific Reports] |
|  |
|
|
|
| Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism.
[Nature Reviews Cardiology] |
|
|
|
| The authors review all the current literature from 1 December 2019 to 7 May 2020 to provide useful information about SARS-CoV2 viral biology, epidemiology, diagnosis, clinical features, treatment, prevention, and hospital organization for clinicians dealing with this selected population.
[Pediatric Research] |
|
|
|
|
| BioAegis Therapeutics Inc. announces that it received regulatory clearance from The Spanish Agency for Medicines and Health Products for its Phase II Proof of Concept study of its lead product, recombinant human plasma gelsolin in hospitalized patients with severe COVID-19 pneumonia.
[BioAegis Therapeutics, Inc. (GlobeNewswire, Inc.)] |
|
|
|
| Valneva SE announced positive initial results for its first Phase II study of Lyme disease vaccine candidate VLA15.
[Valneva SE] |
|
|
|
| In a sad knock-on effect of the COVID-19 pandemic, the Global Polio Eradication Initiative abruptly halted all mass vaccination campaigns in March, worried they could inadvertently spread the novel coronavirus. But now, armed with new data and perspective, GPEI and the countries it supports are resuming vaccination campaigns.
[ScienceInsider] |
|
|
|
| Health officials who fought Ebola during the world’s deadliest outbreak of the disease in Liberia, Sierra Leone and Guinea have resurrected the tools they used during that crisis to stave off the coronavirus.
[Nature News] |
|
|
|
| Scientists caution against comparing immune responses shown in early-stage trials, and say there might be more than one path to an effective vaccine.
[Nature News] |
|
|
|
| In prepared remarks for a US congressional hearing, several companies vowed to include broad representation as they prepare to launch studies with thousands of volunteers in the coming months.
[Reuters] |
|
|
|
|
| August 27 – August 29
Virtual |
|
|
|
|
|
| | University of Dundee – Dundee, United Kingdom |
|
|
|
| | University of Würzburg – Würzburg, Germany |
|
|
|
| | Ohio State University – Columbus, Ohio, United States |
|
|
|
| | Terasaki Institute for Biomedical Innovation – Los Angeles, California, United States |
|
|
|
| | Lund University – Lund, Sweden |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
